tiprankstipranks
Trending News
More News >
Innate Pharma (IPHA)
NASDAQ:IPHA
US Market
Advertisement

Innate Pharma (IPHA) Income Statement

Compare
118 Followers

Innate Pharma Income Statement

Last quarter (Q4 2024), Innate Pharma's total revenue was €276.00K, a decrease of -96.68% from the same quarter last year. In Q4, Innate Pharma's net income was €-24.71M. See Innate Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
€ 12.62M€ 51.90M€ 57.67M€ 12.11M€ 69.77M
Gross Profit
€ 12.62M€ -4.12M€ -2.02M€ -34.89M€ 20.07M
Operating Expenses
€ 64.20M€ 64.57M€ 66.06M€ 59.94M€ 18.99M
Depreciation and Amortization
€ 1.99M€ 5.09M€ 45.41M€ 4.57M€ 12.23M
EBITDA
€ -46.91M€ -1.84M€ -12.28M€ -43.23M€ 13.30M
Operating Income
€ -51.58M€ -12.67M€ -57.42M€ -47.83M€ 1.08M
Other Income/Expenses
€ 2.10M€ 5.10M€ -547.00K€ 2.35M€ -1.91M
Pretax Income
€ -49.47M€ -7.57M€ -57.97M€ -45.48M€ -829.00K
Net Income
€ -49.47M€ -7.57M€ -58.10M€ -59.14M€ -63.98M
Per Share Metrics
Basic EPS
€ -0.61€ -0.09€ -0.73€ -0.74€ -0.01
Diluted EPS
€ -0.61€ -0.09€ -0.73€ -0.74€ -0.01
Weighted Average Shares Outstanding
81.05M 84.11M 79.59M 79.54M 78.93M
Weighted Average Shares Outstanding (Diluted)
81.05M 84.11M 79.64M 79.54M 78.93M
Currency in EUR

Innate Pharma Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis